MPX-004 and MPX-007: New pharmacological tools to study the physiology of nmda receptors containing the GluN2A Subunit

PLoS ONE

Volumn 11, Issue 2, 2016, Pages

  Volkmann, Robert A ^a   Fanger, Christopher M ^a   Anderson, David R ^a   Sirivolu, Venkata Ramana ^b   Paschetto, Kathy ^c   Gordon, Earl ^c   Virginio, Caterina ^d   Gleyzes, Melanie ^e   Buisson, Bruno ^e   Steidl, Esther ^e   Mierau, Susanna B ^f   Fagiolini, Michela ^f   Menniti, Frank S ^a  

^a Mnemosyne Pharmaceuticals   (United States)

^b JUBILANT BIOSYS LTD   (India)

^c Jubilant Discovery Services   (United States)

^d Aptuit Inc   (United States)

^e Neuroservice   (France)

^f BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 [[(3 CHLORO 4 FLUOROPHENYL)SULFONAMIDO]METHYL] N [(2 METHYLTHIAZOL 5 YL)METHYL]PYRAZINE 2 CARBOXAMIDE; 5 [[(3 FLUORO 4 FLUOROPHENYL)SULFONAMIDO]METHYL] N [(2 METHYLTHIAZOL 5 YL)METHYL]PYRAZINE 2 CARBOXAMIDE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR GLUN2A SUBUNIT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR GLUN2B SUBUNIT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR GLUN2D SUBUNIT; UNCLASSIFIED DRUG; AMPA RECEPTOR; CALCIUM; GLUTAMIC ACID; GLYCINE; MPX-004; MPX-007; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; NR2D NMDA RECEPTOR; PROTEIN SUBUNIT; PYRAZINE DERIVATIVE; SULFONAMIDE; TCN 201;

ANIMAL CELL; ARTICLE; BRAIN CORTEX SLICE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEVELOPMENTAL DISORDER; ELECTROPHYSIOLOGY; EMBRYO; EXCITATORY POSTSYNAPTIC POTENTIAL; FEMALE; HEK293 CELL LINE; HIPPOCAMPAL SLICE; HUMAN; HUMAN CELL; IC50; ION CURRENT; KNOCKOUT MOUSE; MENTAL DISEASE; NONHUMAN; OOCYTE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PYRAMIDAL NERVE CELL; RAT; RECEPTOR SENSITIVITY; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION; XENOPUS; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHANNEL GATING; CHEMISTRY; CYTOLOGY; DOG; DRUG EFFECTS; HIPPOCAMPAL CA1 REGION; MALE; MDCK CELL LINE; METABOLISM; NERVE CELL; PROTEIN SUBUNIT; SPRAGUE DAWLEY RAT;

ANIMALS; CA1 REGION, HIPPOCAMPAL; CALCIUM; CELLS, CULTURED; DOGS; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; GLUTAMIC ACID; GLYCINE; HUMANS; ION CHANNEL GATING; MADIN DARBY CANINE KIDNEY CELLS; MALE; NEURONS; OOCYTES; PROTEIN SUBUNITS; PYRAZINES; RATS, SPRAGUE-DAWLEY; RECEPTORS, AMPA; RECEPTORS, N-METHYL-D-ASPARTATE; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; XENOPUS;

EID: 84958817607     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0148129     Document Type: Article

References (58)

1. Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O, Gaiarsa JL. GABAA, NMDA and AMPA receptors: a developmentally regulated 'menage a trois'. Trends Neurosci. 1997; 20(11):523-9. PMID: 9364667.
2. Traynelis SF, Wollmuth LP, McBain CJ, Menniti FS, Vance KM, Ogden KK, et al. Glutamate Receptor Ion Channels: Structure, Regulation, and Function. Pharmacological Reviews. 2010; 62:405-96. doi: 10.1124/pr.109.002451 PMID: 20716669
3. Conn PJ, Pin JP. Pharmacology and functions of metabotropic glutamate receptors. Annu Rev Pharmacol Toxicol. 1997; 37:205-37. doi: 10.1146/annurev.pharmtox.37.1.205 PMID: 9131252.
4. Bliss TVP, Collingridge GL. Memories of NMDA receptors and LTP. Trends in Neurosciences. 1993; 18 (2):54.
5. Shepherd JD, Huganir RL. The Cell Biology of Synaptic Plasticity: AMPA Receptor Trafficking. Annual Review of Cell and Developmental Biology. 2007; 23(1):613-43.
6. Paoletti P, Bellone C, Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nature Reviews Neuroscience. 2013; 14(6):383-400. doi: 10.1038/nrn3504 PMID: 23686171
7. Kantrowitz JT, Javitt DC. N-methyl-d-Aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia Brain Res Bull. 2010; 83(3-4):108-21. Epub 2010/04/27. doi: 10.1016/j.brainresbull.2010.04.006 PMID: 20417696; PubMed Central PMCID: PMC2941541.
8. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology. 2003; 169(3-4):215-33. doi: 10.1007/s00213-003-1582-z PMID: 12955285
9. Olney JW, Farber NB. NMDA antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia. Neuropsychopharmacology. 1995; 13(4):335-45. PMID: 8747758.
10. Zhou Q, Sheng M. NMDA receptors in nervous system diseases. Neuropharmacology. 2013; 74:69-75. doi: 10.1016/j.neuropharm.2013.03.030 PMID: 23583930.
11. Lee CH, Lu W, Michel JC, Goehring A, Du J, Song X, et al. NMDA receptor structures reveal subunit arrangement and pore architecture. Nature. 2014; 511(7508):191-7. doi: 10.1038/nature13548 PMID: 25008524.
12. Karakas E, Furukawa H. Crystal structure of a heterotetrameric NMDA receptor ion channel. Science. 2014; 344(6187):992-7. doi: 10.1126/science.1251915 PMID: 24876489; PubMed Central PMCID: PMC4113085.
13. Monyer H, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH. Developmental and regional expression in the rat brain and functional properties of four NMDA receptors. Neuron. 1994; 12(3):529-40. Epub 1994/03/01. doi: 0896-6273(94)90210-0 [pii]. PMID: 7512349.
14. Ishii T, Moriyoshi K, Sugihara H, Sakurada K, Kadotani H, Yokoi M, et al. Molecular characterization of the family of the N-methyl-D-Aspartate receptor subunits. J Biol Chem. 1993; 268(4):2836-43. Epub 1993/02/05. PMID: 8428958.
15. Cull-Candy SG, Leszkiewicz DN. Role of Distinct NMDA Receptor Subtypes at Central Synapses. Science STKE. 2004; 16:1-9.
16. Yuan H, Hansen KB, Vance KM, Ogden KK, Traynelis SF. Control of NMDA Receptor Function by the NR2 Subunit Amino-Terminal Domain. Journal of Neuroscience. 2009; 29(39):12045-58. doi: 10.1523/jneurosci.1365-09.2009 PMID: 19793963
17. Standaert DG, Testa CM, Young AB, Penney JB Jr. Organization of N-methyl-D-Aspartate glutamate receptor gene expression in the basal ganglia of the rat. J Comp Neurol. 1994; 343(1):1-16. doi: 10. 1002/cne.903430102 PMID: 8027428.
18. Ogden KK, Traynelis SF. New advances in NMDA receptor pharmacology. Trends Pharmacol Sci. 2011; 32(12):726-33. doi: 10.1016/j.tips.2011.08.003 PMID: 21996280; PubMed Central PMCID: PMC3223280.
19. Monaghan DT, Irvine MW, Costa BM, Fang G, Jane DE. Pharmacological modulation of NMDA receptor activity and the advent of negative and positive allosteric modulators. Neurochemistry International. 2012. Epub 2012/01/25. doi: 10.1016/j.neuint.2012.01.004 PMID: 22269804.
20. Kew JNC, Kemp JA. Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology. 2005; 179(1):4-29. doi: 10.1007/s00213-005-2200-z PMID: 15731895
21. Small D, Tauskela J. Glutamate Receptor Pharmacology: Lessons Learned from the Last Decade of Stroke Trials. Glutamate Receptors in Peripheral Tissue: Excitatory Transmission Outside the CNS2005. p. 27-45.
22. Layton ME, Kelly MJ 3rd, Rodzinak KJ. Recent advances in the development of NR2B subtype-selective NMDA receptor antagonists. Curr Top Med Chem. 2006; 6(7):697-709. Epub 2006/05/25. PMID: 16719810.
23. Chenard BL, Menniti FS. Antagonists selective for NMDA receptors containing the NR2B subunit. Curr Pharm Des. 1999; 5(5):381-404. Epub 1999/04/24. PMID: 10213801.
24. Bettini E, Sava A, Griffante C, Carignani C, Buson A, Capelli AM, et al. Identification and characterization of novel NMDA receptor antagonists selective for NR2A-over NR2B-containing receptors. Journal of Pharmacology and Experimental Therapeutics. 2010; 335(3):636-44. Epub 2010/09/03. doi: 10. 1124/jpet.110.172544 PMID: 20810618.
25. Hansen KB, Mullasseril P, Dawit S, Kurtkaya NL, Yuan H, Vance KM, et al. Implementation of a fluorescence-based screening assay identifies histamine H3 receptor antagonists clobenpropit and iodophenpropit as subunit-selective N-methyl-D-Aspartate receptor antagonists. J Pharmacol Exp Ther. 2010; 333(3):650-62. Epub 2010/03/04. doi: 10.1124/jpet.110.166256 PMID: 20197375; PubMed Central PMCID: PMC2879924.
26. Hansen KB, Ogden KK, Traynelis SF. Subunit-selective allosteric inhibition of glycine binding to NMDA receptors. Journal of Neuroscience. 2012; 32(18):6197-208. Epub 2012/05/04. doi: 10.1523/JNEUROSCI.5757-11.2012 PMID: 22553026; PubMed Central PMCID: PMC3355950.
27. Anderson DR, Volkmann RA. N-ARYLMETHYL SULFONAMIDE NEGATIVE MODULATORS OF NR2A. US Patent 20,150,141,433; 2015.
28. Dupuis DS, Klaerke DA, Olesen SP. Effect of beta-Adrenoceptor blockers on human ether-A-go-gorelated gene (HERG) potassium channels. Basic Clin Pharmacol Toxicol. 2005; 96(2):123-30. doi: 10. 1111/j.1742-7843.2005.pto960206.x PMID: 15679475.
29. Fischer G, Mutel V, Trube G, Malherbe P, Kew JN, Mohacsi E, et al. Ro 25-6981, a highly potent and selective blocker of N-methyl-D-Aspartate receptors containing the NR2B subunit. Characterization in vitro. J Pharmacol Exp Ther. 1997; 283(3):1285-92. Epub 1998/02/12. PMID: 9400004.
30. Durand S, Patrizi A, Quast KB, Hachigian L, Pavlyuk R, Saxena A, et al. NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron. 2012; 76(6):1078-90. doi: 10.1016/j.neuron.2012.12.004 PMID: 23259945; PubMed Central PMCID: PMC3733788.
31. Edman S, McKay S, Macdonald LJ, Samadi M, Livesey MR, Hardingham GE, et al. TCN 201 selectively blocks GluN2A-containing NMDARs in a GluN1 co-Agonist dependent but non-competitive manner. Neuropharmacology. 2012; 63(3):441-9. Epub 2012/05/15. doi: 10.1016/j.neuropharm.2012.04.027 PMID: 22579927.
32. Gipson CD, Reissner KJ, Kupchik YM, Smith AC, Stankeviciute N, Hensley-Simon ME, et al. Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. Proc Natl Acad Sci U S A. 2013; 110 (22):9124-9. doi: 10.1073/pnas.1220591110 PMID: 23671067; PubMed Central PMCID: PMCPMC3670307.
33. Wu F, Echeverry R,Wu J, An J, Haile WB, Cooper DS, et al. Tissue-type plasminogen activator protects neurons from excitotoxin-induced cell death via activation of the ERK1/2-CREB-ATF3 signaling pathway. Mol Cell Neurosci. 2013; 52:9-19. doi: 10.1016/j.mcn.2012.10.001 PMID: 23063501; PubMed Central PMCID: PMCPMC3540185.
34. Tovar KR, McGinley MJ, Westbrook GL. Triheteromeric NMDA Receptors at Hippocampal Synapses. The Journal of Neuroscience. 2013; 33(21):9150-60. doi: 10.1523/JNEUROSCI.0829-13.2013 PMID: 23699525
35. Soares C, Lee KF. A prominent role for triheteromeric GluN1/GluN2A/GluN2B NMDARs at central synapses. J Neurosci. 2013; 33(38):14975-7. doi: 10.1523/JNEUROSCI.3109-13.2013 PMID: 24048825.
36. Rauner C, Kohr G. Triheteromeric NR1/NR2A/NR2B receptors constitute the major N-methyl-D-Aspartate receptor population in adult hippocampal synapses. J Biol Chem. 2011; 286(9):7558-66. Epub 2010/12/31. doi: 10.1074/jbc.M110.182600 PMID: 21190942; PubMed Central PMCID: PMC3045010.
37. Hansen KB, Ogden KK, Yuan H, Traynelis SF. Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. Neuron. 2014; 81(5):1084-96. doi: 10.1016/j. neuron.2014.01.035 PMID: 24607230; PubMed Central PMCID: PMC3957490.
38. Cull-Candy SG, Brickley S, Farrant M. NMDA receptor subunits: diversity, development and disease. Current Opinion in Neurobiology. 2001; 11:327-35. PMID: 11399431
39. Stocca G, Vicini S. Increased contribution of NR2A subunit to synaptic NMDA receptors in developing rat cortical neurons. The Journal of Physiology. 1998; 507 (Pt 1):13-24. Epub 1998/04/04. PMID: 9490809; PubMed Central PMCID: PMC2230772.
40. Philpot BD, Cho KK, Bear MF. Obligatory role of NR2A for metaplasticity in visual cortex. Neuron. 2007; 53(4):495-502. Epub 2007/02/14. doi: 10.1016/j.neuron.2007.01.027 PMID: 17296552; PubMed Central PMCID: PMC1847797.
41. Quinlan EM, Olstein DH, Bear MF. Bidirectional, experience-dependent regulation of N-methyl-Daspartate receptor subunit composition in the rat visual cortex during postnatal development. Proc Natl Acad Sci U S A. 1999; 96(22):12876-80. PMID: 10536016
42. Fagiolini M, Katagiri H, Miyamoto H, Mori H, Grant SG, Mishina M, et al. Separable features of visual cortical plasticity revealed by N-methyl-D-Aspartate receptor 2A signaling. Proc Natl Acad Sci U S A. 2003; 100(5):2854-9. doi: 10.1073/pnas.0536089100 PMID: 12591944; PubMed Central PMCID: PMC151430.
43. Sheng M, Cummings J, Roldan LA, Jan YN, Jan LY. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex. Nature. 1994; 368(6467):144-7. doi: 10.1038/368144a0 PMID: 8139656.
44. Gambrill AC, Barria A. NMDA receptor subunit composition controls synaptogenesis and synapse stabilization. Proc Natl Acad Sci U S A. 2011; 108(14):5855-60. Epub 2011/03/24. doi: 10.1073/pnas. 1012676108 PMID: 21427228.
45. Yashiro K, Philpot B. Regulation of NMDA receptor subunit expression and its implications for LTD, LTP, and metaplasticity. Neuropharmacology. 2008; 55(7):1081-94. doi: 10.1016/j.neuropharm.2008. 07.046 PMID: 18755202
46. Lee MC, Yasuda R, Ehlers MD. Metaplasticity at single glutamatergic synapses. Neuron. 2010; 66 (6):859-70. Epub 2010/07/14. doi: 10.1016/j.neuron.2010.05.015 PMID: 20620872; PubMed Central PMCID: PMC2911980.
47. Fromer M, Pocklington AJ, Kavanagh DH, Williams HJ, Dwyer S, Gormley P, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014; 506(7487):179-84. doi: 10.1038/nature12929 PMID: 24463507; PubMed Central PMCID: PMCPMC4237002.
48. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, et al. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011; 168(9):930-46. doi: 10.1176/appi.ajp.2011.10050723 PMID: 21498463; PubMed Central PMCID: PMCPMC3751972.
49. Barnby G, Abbott A, Sykes N, Morris A, Weeks D, Mott R, et al. Candidate-Gene Screening and Association Analysis at the Autism-Susceptibility Locus on Chromosome 16p: Evidence of Association at GRIN2A and ABAT. The American Journal of Human Genetics. 2005; 76(6):950-66. doi: 10.1086/430454 PMID: 15830322
50. Endele S, Rosenberger G, Geider K, Popp B, Tamer C, Stefanova I, et al. Mutations in GRIN2A and GRIN2B encoding regulatory subunits of NMDA receptors cause variable neurodevelopmental phenotypes. Nature Genetics. 2010; 42(11):1021-6. doi: 10.1038/ng.677 PMID: 20890276
51. Carvill GL, Regan BM, Yendle SC, O'Roak BJ, Lozovaya N, Bruneau N, et al. GRIN2A mutations cause epilepsy-Aphasia spectrum disorders. Nat Genet. 2013; 45(9):1073-6. doi: 10.1038/ng.2727 PMID: 23933818; PubMed Central PMCID: PMCPMC3868952.
52. Lemke JR, Lal D, Reinthaler EM, Steiner I, Nothnagel M, Alber M, et al. Mutations in GRIN2A cause idiopathic focal epilepsy with rolandic spikes. Nat Genet. 2013; 45(9):1067-72. Epub 2013/08/13. doi: 10. 1038/ng.2728 PMID: 23933819.
53. Lesca G, Rudolf G, Bruneau N, Lozovaya N, Labalme A, Boutry-Kryza N, et al. GRIN2A mutations in acquired epileptic aphasia and related childhood focal epilepsies and encephalopathies with speech and language dysfunction. Nat Genet. 2013; 45(9):1061-6. doi: 10.1038/ng.2726 PMID: 23933820.
54. Mierau SB, Patrizi A, Hensch TK, Fagiolini M. Cell-Specific Regulation of N-Methyl-D-Aspartate Receptor Maturation by Mecp2 in Cortical Circuits. Biol Psychiatry. 2015. doi: 10.1016/j.biopsych.2015.05. 018 PMID: 26185009.
55. Hallett PJ, Dunah AW, Ravenscroft P, Zhou S, Bezard E, Crossman AR, et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology. 2005; 48(4):503-16. doi: 10.1016/j.neuropharm. 2004.11.008 PMID: 15755478.
56. Gardoni F, Sgobio C, Pendolino V, Calabresi P, Di Luca M, Picconi B. Targeting NR2A-containing NMDA receptors reduces L-DOPA-induced dyskinesias. Neurobiol Aging. 2012; 33(9):2138-44. doi: 10.1016/j.neurobiolaging.2011.06.019 PMID: 21821315.
57. Anderson DR, Volkmann RA, Menniti FS. Selective octahydro-cyclopenta[c] pyrrole negative modulators of nr2b. Google Patents; 2015.
58. Steidl EM, Neveu E, Bertrand D, Buisson B. The adult rat hippocampal slice revisited with multi-electrode arrays. Brain Res. 2006; 1096(1):70-84. doi: 10.1016/j.brainres.2006.04.034 PMID: 16716268.